{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:22:47Z","timestamp":1781187767072,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["XDB0540000"],"award-info":[{"award-number":["XDB0540000"]}]},{"DOI":"10.13039\/501100019490","name":"Yalong River Joint Fund","doi-asserted-by":"publisher","award":["22327901"],"award-info":[{"award-number":["22327901"]}],"id":[{"id":"10.13039\/501100019490","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["22374155"],"award-info":[{"award-number":["22374155"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Exosomes play a crucial role in the transmission of drug resistance in tumors. However, the mechanism of exosomes-mediated transmission in non-small cell lung cancer (NSCLC) under gefitinib treatment remains limited. In this work, we demonstrated that exosomes derived from HCC827\/GR cells (drug-resistant) enhanced the survivability of HCC827 cells (drug-sensitive) under treatment with gefitinib. A total of 157 shared upregulated proteins between exosomes and their parent cells were identified in the comparison of the gefitinib-resistant groups versus the gefitinib-sensitive groups. Notably, 69 of these shared proteins are enzymes, and many of them were enriched in pathways related to fatty acid metabolism. Among these enzymes involved in fatty acid metabolism, ACC1 exhibited the highest fold change in upregulated expression in both drug-resistant groups (exosomes and cells). Moreover, the expression of ACC1 was upregulated in gefitinib-sensitive cells after uptake of exosomes from gefitinib-resistant cells. The role of ACC1 in enhancing the survival of HCC827\/GR cells under gefitinib treatment was demonstrated using an inhibitor and siRNA-mediated knockdown. Specifically, the upregulated ACC1 stabilized fatty acid oxidation and reactive oxygen species levels in HCC827\/GR cells, thereby maintaining cellular metabolic homeostasis. Collectively, this work reveals the transmission of drug resistance in NSCLC via exosomes that carry the ACC1 protein.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s10565-025-10121-8","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:26:57Z","timestamp":1766125617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exosomal proteomics reveals fatty acid metabolism linked to gefitinib resistance in non-small cell lung cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Yuanyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"10121_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","volume":"19","author":"NK Altorki","year":"2019","unstructured":"Altorki NK, Markowitz GJ, Gao D, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019;19:9\u201331.","journal-title":"Nat Rev Cancer"},{"key":"10121_CR2","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"10121_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102664","volume":"122","author":"F Ciardiello","year":"2024","unstructured":"Ciardiello F, Hirsch FR, Pirker R, Felip E, Valencia C, Smit EF. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. Cancer Treat Rev. 2024;122:102664.","journal-title":"Cancer Treat Rev"},{"key":"10121_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","volume":"30","author":"M Colombo","year":"2014","unstructured":"Colombo M, Raposo G, Th\u00e9ry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255\u201389.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10121_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104683","volume":"153","author":"KGK Deepak","year":"2020","unstructured":"Deepak KGK, Vempati R, Nagaraju GP, et al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020;153:104683.","journal-title":"Pharmacol Res"},{"key":"10121_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94:1623\u201340.","journal-title":"Mayo Clin Proc"},{"key":"10121_CR7","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/nm.3372","volume":"19","author":"MD Fullerton","year":"2013","unstructured":"Fullerton MD, Galic S, Marcinko K, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med. 2013;19:1649\u201354.","journal-title":"Nat Med"},{"key":"10121_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19:121\u201335.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10121_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20:74\u201388.","journal-title":"Nat Rev Cancer"},{"key":"10121_CR10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41568-021-00388-4","volume":"21","author":"AJ Hoy","year":"2021","unstructured":"Hoy AJ, Nagarajan SR, Butler LM. Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nat Rev Cancer. 2021;21:753\u201366.","journal-title":"Nat Rev Cancer"},{"key":"10121_CR11","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cmet.2021.08.006","volume":"33","author":"R Isaac","year":"2021","unstructured":"Isaac R, Reis FCG, Ying W, Olefsky JM. Exosomes as mediators of intercellular crosstalk in metabolism. Cell Metab. 2021;33:1744\u201362.","journal-title":"Cell Metab"},{"key":"10121_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.canlet.2020.01.003","volume":"473","author":"MA Khan","year":"2020","unstructured":"Khan MA, Zubair H, Anand S, Srivastava SK, Singh S, Singh AP. Dysregulation of metabolic enzymes in tumor and stromal cells: role in oncogenesis and therapeutic opportunities. Cancer Lett. 2020;473:176\u201385.","journal-title":"Cancer Lett"},{"key":"10121_CR13","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.4161\/onci.22194","volume":"1","author":"G Klein","year":"2012","unstructured":"Klein G. Tumor resistance. Oncoimmunology. 2012;1:1355\u20139.","journal-title":"Oncoimmunology"},{"key":"10121_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-021-01463-y","volume":"20","author":"C Li","year":"2021","unstructured":"Li C, Teixeira AF, Zhu HJ, Ten Dijke P. Cancer associated-fibroblast-derived exosomes in cancer progression. Mol Cancer. 2021;20:154.","journal-title":"Mol Cancer"},{"key":"10121_CR15","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/jcmm.14838","volume":"24","author":"X Liu","year":"2020","unstructured":"Liu X, Jiang T, Li X, et al. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K\/AKT signalling pathway. J Cell Mol Med. 2020;24:1529\u201340.","journal-title":"J Cell Mol Med"},{"key":"10121_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-12734-3_1","volume":"1136","author":"W Luo","year":"2019","unstructured":"Luo W, Wang Y. Hypoxia mediates tumor malignancy and therapy resistance. Adv Exp Med Biol. 2019;1136:1\u201318.","journal-title":"Adv Exp Med Biol"},{"key":"10121_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-019-0991-5","volume":"18","author":"L Mashouri","year":"2019","unstructured":"Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019;18:75.","journal-title":"Mol Cancer"},{"key":"10121_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423\u201337.","journal-title":"Nat Med"},{"key":"10121_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4103\/1477-3163.123972","volume":"12","author":"T Reungwetwattana","year":"2013","unstructured":"Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog. 2013;12:22.","journal-title":"J Carcinog"},{"key":"10121_CR20","doi-asserted-by":"crossref","unstructured":"S ELA, M\u00e4ger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013;12:347-57.","DOI":"10.1038\/nrd3978"},{"key":"10121_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188967","volume":"1878","author":"S Singh","year":"2023","unstructured":"Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: insight and foresight. Biochim Biophys Acta Rev Cancer. 2023;1878:188967.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10121_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.molmed.2015.08.002","volume":"21","author":"D Sousa","year":"2015","unstructured":"Sousa D, Lima RT, Vasconcelos MH. Intercellular transfer of cancer drug resistance traits by extracellular vesicles. Trends Mol Med. 2015;21:595\u2013608.","journal-title":"Trends Mol Med"},{"key":"10121_CR23","doi-asserted-by":"publisher","DOI":"10.3410\/B3-15","volume":"3","author":"C Th\u00e9ry","year":"2011","unstructured":"Th\u00e9ry C. Exosomes: secreted vesicles and intercellular communications. F1000 Biol Rep. 2011;3:15.","journal-title":"F1000 Biol Rep"},{"key":"10121_CR24","doi-asserted-by":"publisher","first-page":"7215","DOI":"10.1038\/s41467-022-34747-y","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Luo M, Wang F, et al. AMPK induces degradation of the transcriptional repressor PROX1 impairing branched amino acid metabolism and tumourigenesis. Nat Commun. 2022;13:7215.","journal-title":"Nat Commun"},{"key":"10121_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2023.100624","volume":"22","author":"PS Wu","year":"2023","unstructured":"Wu PS, Lin MH, Hsiao JC, Lin PY, Pan SH, Chen YJ. EGFR-T790M mutation-derived interactome rerouted EGFR translocation contributing to gefitinib resistance in non-small cell lung cancer. Mol Cell Proteomics. 2023;22:100624.","journal-title":"Mol Cell Proteomics"},{"key":"10121_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cytogfr.2023.05.002","volume":"73","author":"L Ye","year":"2023","unstructured":"Ye L, Li Y, Zhang S, Wang J, Lei B. Exosomes-regulated lipid metabolism in tumorigenesis and cancer progression. Cytokine Growth Factor Rev. 2023;73:27\u201339.","journal-title":"Cytokine Growth Factor Rev"},{"key":"10121_CR27","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.trecan.2019.09.008","volume":"5","author":"VW Zhu","year":"2019","unstructured":"Zhu VW, Klempner SJ, Ou SI. Receptor tyrosine kinase fusions as an actionable resistance mechanism to EGFR TKIs in EGFR-mutant non-small-cell lung cancer. Trends Cancer. 2019;5:677\u201392.","journal-title":"Trends Cancer"}],"container-title":["Cell Biology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-025-10121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10565-025-10121-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-025-10121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:27:00Z","timestamp":1766125620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10565-025-10121-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10121"],"URL":"https:\/\/doi.org\/10.1007\/s10565-025-10121-8","relation":{},"ISSN":["1573-6822"],"issn-type":[{"value":"1573-6822","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments adhered strictly to the regulations set by the Animal Research Management Committee in Shouzheng Pharma (Wuhan) Biotechnology Co., Ltd. (IACUC Number: SZHY 2025102101).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}